Session Title: Vitreoretinal Surgery II
Session Date/Time: Thursday 26/09/2013 | 14:30-16:00
Paper Time: 14:38
Venue: Hall 3 (Level 0)
First Author: N.Arend GERMANY
Co Author(s): C. Wertheimer R. Liegl A. Wolf K. Eibl
Proliferative vitreoretinopathy (PVR) is a feared complication of retinal detachment surgery. Even if the pathogenesis is still not fully understood, there is evidence that cytokines and growth factors are involved and that the proteinkinase „mammalian target of rapamycin“ (mTOR) plays a pivotal role in regulation of cell growth, proliferation and migration. The present study evaluates potential anti-proliferative, anti-migrative and anti-contractive effects of the mTOR inhibitor Everolimus on human retinal pigment epithelium cells (RPE) and Muller glia cells (MioM1), regarding a possible treatment option for PVR.
RPE and MioM1 were treated with 0.00001 to 100µg/ml Everolimus. Cellular vitality and proliferation were examined by MTT-essay. Cell migration was detected using Boyden chamber migration essay and contraction by 3D collagen matrix cell contraction essay.
Everolimus showed no toxic effect up to a concentration of 10µg/ml in MioM1 and RPE. A concentration of 0.01µg/ml in MioM1 and 0.05µg/ml in RPE cells showed 50 percent reduction in proliferation rate. Cell Migration and contraction were significantly inhibited by Everolimus in both tested cell lines in a dose dependent manner.
The present study showed significant anti-proliferative, anti-migrative and anti-contractive effects of Everolimus on RPE and Muller cells. These in vitro results provide early evidence that Everolimus and the inhibition of mTOR may have properties for prevention and treatment of PVR in vivo.